Rivastigmine (Exelon®)

Pharmaceutisch Weekblad

Volumn 134, Issue 30, 1999, Pages 998-1002

  Van Schaik, B A M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; DIAZEPAM; DIGOXIN; DONEPEZIL; FLUOXETINE; MUSCARINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PYRIDINE DERIVATIVE; RIVASTIGMINE; TACRINE; WARFARIN;

ADULT; AGED; ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG ELIMINATION; FEMALE; GAS CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; REVIEW; SICK SINUS SYNDROME; STOMACH ULCER;

EID: 19244381400     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Scheltens P. De huidige medicamenteuze behandeling van de ziekte van Alzheimer. Neuropraxis 1998;2(4):142-5.
2. Verhey FRJ, Heeren TJ, Scheltens P, et al. Cholinesteraseremmers bij de ziekte van Alzheimer: voorlopige aanbevelingen voor de praktijk. Ned Tijdschr Geneeskd 1998;142(38):2091-6.
3. Maring JG, Eppinga M. Cholinesteraseremmers bij Alzheimer. Pharma Selecta 1999;15:17-20.
4. Farlow MR. Etiology and pathogenesis of Alzheimer's disease. Am J Health-Syst Pharm 1998;55 suppl 2:S5-10.
5. Simonson W. Promising agents for treating Alzheimer's disease. Am J Health-Syst Pharm 1998;55 suppl 2:S11-6.
6. Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health-Syst Pharm 1998;55 suppl 2:S22-5.
7. Enz A, Floersheim P. Cholinesterase inhibitors: an overview of their mechanisms of action. In: Becker R, Giacobini E, red. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996:211-5.
8. Anand R, Gharabawi G. Clinical development of Exelon (ENA-713): The ADENA programme. J Drug Dev Clin Pract 1996;8(2):9-14.
9. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998;1:55-65.
10. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999;318:633-8.
11. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996;8(2):1-8.
12. Sramek JJ, Anand R, Wardle TS, et al. Safety/tolerability trial of SDZ EA 713 in patients with probable Alzheimer's disease. Life Sci 1996;58(15):1201-7.